Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between May 12, 2022 and August 11, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2022. SO WHAT: If you purchased Co-Diagnostics securities during the Class Period you may be entitled to compensa

EQUITY ALERT: Rosen Law Firm Encourages Co-Diagnostics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CODX

Investors continued to avoid the company after its big second-quarter whiffs.

Why Co-Diagnostics Stock Slipped Today

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman, President and Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Robert Burns - H.C. Wainwright & Co., LLC James Sidoti - Sidoti & Company, LLC Theodore O'Neill - Litchfield Hills Research, LLC Operator Good afternoon, and welcome to the Co-Diagnostics' Second Quarter 2022 Earnings Conference Call.

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q2 2022 Results - Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -166.67% and 75.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates

Co-Diagnostics Inc (NASDAQ:CODX) ended its second quarter of 2022 with a cash balance of US$96 million to help it progress development of its Co-Dx PCR Home testing platform for infectious diseases. During the three-month period to end June 30, 2022, the company completed the principal design for a monkeypox virus test and shipped testing reagents to its international distributor.

Co-Diagnostics ends 2Q with $96M in cash, expands infectious disease testing menu to include monkeypox

Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform SALT LAKE CITY , Aug. 11, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial Results: Revenue of $5.0 million, down from $27.4 million during the prior year period, due primarily to lower demand of the Logix Smart™ COVID-19 Test Gross profit of $4.1 million, representing 81.8% of consolidated revenue stemming from inefficiencies in lower sales volumes Operating loss of $4.1 million compared to operating income of $11.8 million a year ago, due to lower sales volumes and continued investments into research and development Net loss of $2.7 million, compared to a net income of $9.8 million in the prior-year second quarter, representing a loss of $0.08 per fully diluted share Adjusted EBITDA loss of $2.3 million Cash, cash equivalents, and marketable securities of $96.0 million as of June 30, 2022 Cash flow from operations of $1.7 million for the second quarter ended June 30, 2022 Dwight Egan, Co-Diagnostics' Chief Executive Officer, remarked "Our second quarter results reflect lower volumes for our Logix Smart™ COVID-19 Test, which we believe is primarily the result of a reduction in mandated testing in travel and public venues and in government funding for testing programs.

Co-Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

The stock dropped two days before reporting second-quarter earnings.

Why Shares of Co-Diagnostics Stock Fell 10% on Tuesday

SALT LAKE CITY , Aug. 2, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASA: COD), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2022 results on Thursday, August 11, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

CO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , July 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be attending and speaking at the Yale School of Public Health SalivaDirect™ Conference held July 28-29 in Chicago, Il. The mission of Yale's SalivaDirect is to advance the use of saliva-based testing as a readily-deployable, sensitive, patient-friendly option that increases access to affordable and equitable infectious disease testing.

Co-Diagnostics, Inc. to Participate in Yale University SalivaDirect™ Conference Held July 28-29 in Chicago

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?

Co-Diagnostics Inc (NASDAQ:CODX) (Co-Dx) has announced that it will be disclosing the global expansion of its original equipment manufacturer (OEM) agreement with Bio Molecular Systems (BMS) at the company's customer and distributor update today at the American Association for Clinical Chemistry's (AACC) Annual Scientific Meeting & Clinical Lab Expo. The molecular diagnostics firm said the expanded branding and distribution OEM agreement increases Co-Diagnostics' approved sales territories to 193 countries worldwide.

Co-Diagnostics set to expand OEM deal with Bio Molecular Systems at AACC expo

SALT LAKE CITY , July 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing the original Rotor-Gene Real-Time PCR instrument, with a reputation for expertise in developing innovative, versatile, robust, and easy-to-use products.

Co-Diagnostics, Inc. to Announce Expansion of OEM Agreement with Bio Molecular Systems at AACC

The Company will also be providing an update to its distributors and other customers on July 26 at 11 am CT. SALT LAKE CITY , July 20, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth to showcase its existing and upcoming suite of diagnostics products and technology applications at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, held July 24-28 at the McCormick Place Convention Center in Chicago, IL, in addition to providing an update for its worldwide network of customers and distributors.

Co-Diagnostics, Inc. to Host Booth at AACC Held July 24-28 in Chicago

CODX stock is up during early afternoon trading as Co-Diagnostics ships out monkeypox testing reagents to help deal with the outbreak. The post CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests appeared first on InvestorPlace.

CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests

The medical test maker just got its new test for monkeypox out the door for the first time.

Why Co-Diagnostics Stock Is Rising Today

Co-Diagnostics (NASDAQ:CODX) Inc announced it has shipped testing reagents for the monkeypox virus, currently exhibiting a multi-country outbreak, to one of its international distributors. In a statement, the molecular diagnostics company said the products shipped were designed and developed on an expedited basis to meet the demands in the distributor's region.

Co-Diagnostics ships monkeypox virus tests to international distributor to fight multi-country outbreak

SALT LAKE CITY , July 11, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak to one of its international distributors. According to the World Health Organization (WHO), monkeypox is a virus originally transmitted to humans from animals, and then transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding.

Co-Diagnostics, Inc. Announces Shipment of Monkeypox Virus Test

Investors in the diagnostics and research outfit received a dose of beneficial news today.

Why Co-Diagnostics Is Running Higher Today

SALT LAKE CITY , June 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th International Biodetection Technologies Conference, held virtually June 28-29, 2022. The Biodetection Technologies Conference is an internationally recognized meeting for experts in detection & identification of biological threats, which this year plans to address the key topics in detection and present the latest R&D and technological innovation in ready-to-market systems.

Co-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual Conference

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?

SALT LAKE CITY , June 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Summer Small Cap Virtual Investor Conference June 15-16, 2022. The presentation will begin at 3:15 p.m.

Co-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference

SALT LAKE CITY , June 9, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 22nd MEDEXPO Africa 2022, held June 9-11 in Nairobi, Kenya. The largest international medical trade exhibition in the country features exhibitors from over 30 countries, all profiling innovative solutions from leaders in the medical technology industry, and targeted toward buyers from across the continent seeking new products, equipment, machinery, services and solutions.

Co-Diagnostics, Inc. to Host Booth at MEDEXPO Africa 2022 in Nairobi, Kenya on June 9-11

The company is not monkeying around with the latest possible global health menace.

Why Co-Diagnostics Trounced the Market on Thursday

Co-Diagnostics (NASDAQ:CODX) Inc, a molecular diagnostics company, has completed the principal design work on a PCR test for the monkeypox virus, the company announced.  Outbreaks of the virus have been reported in roughly 20 countries (primarily in Europe) where it is not endemic, with more than 200 confirmed or suspected infections, according to reporting from Reuters and others.

Co-Diagnostics develops principal design work on monkeypox PCR test

SALT LAKE CITY , May 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak. According to the World Health Organization (WHO), monkeypox is a virus originally transmitted to humans from animals, and then transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding.

News for Co-Diagnostics Stock (CODX)